Molecular pathways of anxiety revealed by knockout mice

Molecular Neurobiology

Volumn 23, Issue 2-3, 2001, Pages 101-119

  Wood, S J ^a   Toth, M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anxiety; Anxiety behavior; Corticotrophin releasing hormone; GABA; Knockout mice; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; CORTICOTROPIN RELEASING FACTOR; GAMMA INTERFERON; MIDKINE; NERVE CELL ADHESION MOLECULE; SEROTONIN;

ANIMAL EXPERIMENT; ANXIETY NEUROSIS; ARTICLE; CELL COMMUNICATION; CYTOKINE RELEASE; GENE CONTROL; GENE EXPRESSION; KNOCKOUT MOUSE; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NEUROTRANSMITTER RELEASE; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 0034758748     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:23:2-3:101     Document Type: Article

References (126)

1. Measurement of anxiety in transgenic mice
2. Behavioral phenotyping of transgenic and knockout mice: Experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests
3. Animal models of 'anxiety': Where next?
4. The use of a plus maze to measure anxiety in the mouse
5. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety
6. Thigmotaxis as a test for anxiolytic activity in rats
7. Neuropharmacological specificity for a simple animal model for the behavioural actions of benzodiazepines
8. Animal models of anxiety based on classical conditioning: The conditioned emotional response (CER) and the fear-potentiated startle effect
9. Animal models for predicting clinical efficacy of anxiolytic drugs: Social behaviour
10. Maudsley reactive and non-reactive rats differ in exploratory behavior but not in learning
11. Genetic analysis of anxiety-related behaviors and responses to benzodiazepine-related drugs in AXB and BXA recombinant inbred mouse strains
12. The neuroanatomical basis of anxiety
13. The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias
14. Emotion circuits in the brain
15. Mechanisms of emotional arousal and lasting declarative memory
16. Neurotransmission in the rat amygdala related to fear and anxiety
17. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety
18. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report
19. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT
20. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: A fractal analysis
21. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder
22. Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation
23. Regulation of anxiety by GABAA receptors in the rat amygdala
24. GABAergic influences on plus-maze behaviour in mice
25. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid
26. Postsynaptic clustering of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin
27. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes
28. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alphal subtype
29. Molecular and neuronal substrate for the selective attenuation of anxiety
30. 5-HT and anxiety: Promises and pitfalls
31. 5-HT receptors as targets for the development of novel anxiolytic drugs: Models, mechanisms and future directions
32. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies
33. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies
34. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
35. Neuropeptide Y: An overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses
36. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models
37. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides
38. Corticotropin releasing factor produces behavioural activation in rats
39. The effects of ICV-CRH on novelty-induced behavior
40. Restraintstress-induced changes in exploratory behavior appear to be mediated by norepinephrine-stimulated release of CRF
41. Corticotrophin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus
42. Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone
43. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior
44. CCK in anxiety and cognitive processes
45. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, choleycystokinin and somatostatin levels in the periaqueductal grey and limbic regions
46. Neurotransmitter functions of mammalian tachykinins
47. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection
48. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats
49. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalization in guinea-pigs and mice
50. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase
51. Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity
52. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour
53. Behavioural characterization of neuropeptide Y knockout mice
54. Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y
55. Interaction between neuropeptide Y and noradrenaline on central catecholamine neurons
56. Neuropeptide Y selectively inhibits slow synaptic potentials in rat dorsal raphe nucleus in vitro by a presynaptic action
57. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin
58. Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats
59. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines
60. Targeted disruption of the orphanin FQ/nociceptin gene increases susceptibility and impairs stress adaptation in mice
61. The influence of targeted deletion of the IFNγ gene on emotional behaviours
62. 1A receptor response in NCAM null mutant mice
63. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors
64. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour
65. -/- mice: Possible role in behavioural and metabolic alterations
66. Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor
67. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins
68. A-receptor clustering results in enhanced anxiety and a bias for threat cues
69. Increased anxiety of mice lacking the serotonin lA receptor
70. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice
71. Serotonin receptor lA knockout: An animal model of anxiety-related disorder
72. Functional rescue of postsynaptic 5-HT1A receptors
73. Genetic inactivation of the serotonin (1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety
74. The mouse 5-hydroxytryptamine lB receptor is localized predominantly on axon terminals
75. Presynaptic serotonin receptors in the central nervous system
76. Enhanced aggressive behaviour in mice lacking 5-HT1B receptor
77. 1B receptor knockout - Behavioural consequences
78. 5-HT1B receptor knockout mice exhibit increased exploratory activity and enhanced spatial memory performance in the morris water maze
79. 1B knockout mice
80. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
81. Urocortin, a novel neuropeptide with anxiogenic-like properties
82. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1
83. Corticotorpin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response and aberrant neuroendocrine development
84. Reduced anxiety-like behaviour and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1
85. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
86. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
87. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
88. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety
89. Dopamine D4 receptor knock-out mice exhibit reduced exploration of novel stimuli
90. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene
91. Behaviour of the transgenic (mREN2)27 rat
92. Learning and anxiety in angiotensin-deficient mice
93. 2a receptor
94. Caffeine-induced anxiogenesis: The role of adenosine, benzodiazepine and noradrenergic receptors
95. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons
96. Alpha-7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating - A behavioural characterization of ACR7-deficient mice
97. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse
98. The actions of nicotine and cocaine in a mouse model of anxiety
99. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test
100. The 5′-flanking region of the mouse adenylyl cyclase type VIII gene imparts tissue-specific expression in transgenic mice
101. Altered stress-induced anxiety in adenylyl cyclase type VIII deficient mice
102. Transcription factors responsive to cAMP
103. Altered emotional and locomotor responses in mice deficient in the transcription factor CREM
104. Abnormal fear response and aggressive behavior in mutant mice deficient for alpha-calcium-calmodulin kinase II
105. The postsynaptic density at glutamatergic synapses
106. The multi-functional calcium/calmodulin-dependent protein kinase: From form to function
107. Mice lacking PKCγ exhibit decreased anxiety
108. Ethanol sensitivity of the GABAA receptor expressed in xenopus oocytes requires 8 amino acids contained in the g2L subunit
109. Mutant mice lacking the γ-isoform of protein kinase C show decreased behavioral actions of ethanol and altered function of γ-aminobutyrate type A receptors
110. Increased fearfulness of fyn tyrosine kinase deficient mice
111. Analysis of NMDA receptor mediated synaptic plasticity using gene targeting: Roles of Fyn and FAK non-receptor tyrosine kinases
112. NCAM140 interacts with the focal adhesion kinase p125(fak) and the SRC-related tyrosine kinase p59(fyn)
113. Fyn tyrosine kinase participates in the compact myelin sheath formation in the central nervous system
114. Behavioural characterization of mdx3cv mice deficient in C-terminal dystrophins
115. The neurobiology of Duchenne muscular dystrophy: Learning lessons from muscle?
116. Glucocorticoid signaling - Multiple variations of a common theme
117. Disruption of glucocoricoid receptor gene in the nervous system results in reduced anxiety
118. (Over)correction of FMR1 deficiency with YAC transgenics: Behavioural and physical features
119. Understanding the molecular basis of fragile X syndrome
120. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
121. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation
122. Physiopharmacological interactions between stress hormones and central serotonergic systems
123. 1A receptor mRNA expression
124. Effect of serotonin in hibition on glucocorticoid and mineralocorticoid expression in various brain structures